Pancreatic Adenocarcinoma Treatment Market

Segmentation by Type (Chemotherapy, Targeted Therapy, and Others); by Affected Area (Exocrine, and Endocrine) – Global Demand Analysis & Opportunity Outlook 2030

Buy Now
Report ID: 3373 | Published On: Feb 08, 2023
Request Free Sample Copy

Global Pancreatic Adenocarcinoma Treatment Market Regional Synopsis

On the basis of geographical analysis, the global pancreatic adenocarcinoma treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the North America is estimated to gather the largest share over the forecast period on the back of well-established healthcare infrastructure, presence of large population suffering from the disease and increasing acceptance of pancreatic treatment procedure in the region. As per the National Cancer Institute, in 2021, 60,430 people in the United States are evaluated to suffer from pancreatic cancer. The total number of cases are predicted to rise by 3.2 percent since the previous year. In addition, strong presence of major market players is also expected to expand the region’s market in the upcoming years. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period, which can be ascribed to the rising occurrence of pancreatic adenocarcinoma and growing establishment of critical care centers in the region.

The global pancreatic adenocarcinoma treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Get more information on this report: Request Sample PDF

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Market Segmentation

Our in-depth analysis of the global pancreatic adenocarcinoma treatment market includes the following segments:

By Type

  • Chemotherapy
  • Targeted Therapy
  • Others

By Affected Area

  • Exocrine
  • Endocrine

Growth Drivers

  • Increasing Geriatric Population Around the World
  • Rising Prevalence of Obesity


  • Lack of Skilled Medical Professionals in Lower Economic Regions

Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • Amgen Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffman-La Roche AG
    • Novartis AG
    • Pfizer Inc.
    • Aduro Biotech Inc.
    • Clovis Oncology Inc.
    • Threshold Pharmaceuticals Inc.
    • NewLink Genetics Corp
    • Infinity Pharmaceuticals Inc.
    • Celgene Corporation

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the pancreatic adenocarcinoma treatment market?

Ans: The major factors driving market growth are increasing geriatric population around the world and rising prevalence of obesity.

2) What would be the CAGR of pancreatic adenocarcinoma treatment market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2022 – 2030.

3) What are the challenges affecting the pancreatic adenocarcinoma treatment market growth?

Ans: Lack of skilled medical professionals in lower economic regions is estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of pancreatic adenocarcinoma treatment market in future?

Ans: Asia Pacific will provide more business opportunities to the market in the future owing to the rising occurrence of pancreatic adenocarcinoma and growing establishment of critical care centers in the region.

5) Who are the major players dominating the pancreatic adenocarcinoma treatment market?

Ans: The major players in the market are Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the pancreatic adenocarcinoma treatment market?

Ans: The market is segmented by type, affected area, and by region.

8) Which segment captures the largest market size in the type segment in the pancreatic adenocarcinoma treatment market?

Ans: The exocrine segment is anticipated to hold largest market size and is estimated to grow at a robust CAGR over the forecast period and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample